Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,459.00    -12.00 (-0.82%)
Bid:
1,459.00
Ask:
1,461.00
Spread: 2.00 (0.137%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

1 Dec 2009 10:03

RNS Number : 3702D
Hikma Pharmaceuticals Plc
01 December 2009
Β 

ο»Ώ

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters.

1.

Name of the issuer

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,Β 

(ii) a disclosure made in accordanceΒ 

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793Β of the Companies Act (2006).

(i)Β & (iii)

3.

Name of person discharging managerial

responsibilities/director

MAZEN DARWAZAH (DIRECTOR)

4.

State whether notification relates to a person

connected with a person discharging managerialΒ responsibilities/director named in 3 and identify theΒ connected person

N/A

5.

Indicate whether the notification is in respect of aΒ holding of the person referred to in 3 or 4 above orΒ in respect of a nonbeneficial

interest 1

3 ABOVE

6.

Description of shares (including class), debentures orΒ derivatives or financial instruments relating to shares

ORDINARY SHARES OF 10P EACH

7.

Name of registered shareholders(s) and, if moreΒ than one, the number of shares held by each ofΒ them

MAZEN DARWAZAH

8.

State the nature of the transaction

EXERCISE OF 160,000Β ORDINARY SHARESΒ AT $0.9075 PER SHAREΒ UNDER THE TERMS OF THE 2004 STOCK OPTION PLAN

9.

Number of shares, debentures or financial

instruments relating to shares acquired

160,000

10.

Percentage of issued class acquired (treasury shares ofΒ that class should not be taken into account whenΒ calculating percentage)

DE MINIMIS

11.

Number of shares, debentures or financial

instruments relating to shares disposed

11,000

12.

Percentage of issued class disposed (treasury shares ofΒ that class should not be taken into account whenΒ calculating percentage)

0.083%

13.

Price per share or value of transaction

504.5p

14.

Date and place of transaction

LONDON

15.

Total holding following notification and totalΒ percentage holding following notification (anyΒ treasury shares should not be taken into accountΒ when calculating percentage)

1,086,591Β (0.567%)

16.

Date issuer informed of transaction

27Β NovemberΒ 2009

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

17.

Date of grant

N/A

18.

Period during which or date on which exercisable

N/A

19.

Total amount paid (if any) for grant of the option

N/A

20.

Description of shares or debentures involved (classΒ and number)

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time ofΒ exercise

N/A

22.

Total number of shares or debentures over whichΒ options held following notification

N/A

23.

Any additional information

N/A

24.

Name of contact and telephone number for queries

VictoriaΒ Hames 0207 399 2766

Name of authorised official of issuer responsible for making notification

Henry Knowles

Date of notification 1 DecemberΒ 2009

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

(1)

An issuer making a notification in respect of a transaction relating to the shares orΒ debentures of the issuer should completeΒ boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of theΒ issuer should completeΒ boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/personΒ discharging managerial responsibilities should completeΒ boxes 1 to 3Β and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to theΒ shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11,Β 13, 14, 16, 23 and 24.


This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
RDSBGBDDDGGGGCB
Date   Source Headline
8th Jun 202610:00 amRNSTransaction in Own Shares
2nd Jun 202612:42 pmRNSDirector/PDMR Shareholding
1st Jun 20264:16 pmRNSTotal Voting Rights
1st Jun 202612:11 pmRNSTransaction in Own Shares
27th May 202610:05 amRNSTransaction in Own Shares
26th May 202610:30 amRNSTransaction in Own Shares
18th May 202610:55 amRNSTransaction in Own Shares
15th May 20269:45 amRNSChange of Registered Office
11th May 20261:10 pmRNSTransaction in Own Shares
6th May 20263:08 pmRNSDirector/PDMR Shareholding
5th May 20269:55 amRNSTransaction in Own Shares
1st May 202610:36 amRNSTotal Voting Rights
28th Apr 20261:29 pmRNSDirector/PDMR Shareholding
27th Apr 202611:55 amRNSTransaction in Own Shares
23rd Apr 20263:42 pmRNSResult of AGM
23rd Apr 20267:00 amRNSTrading Statement
20th Apr 202610:55 amRNSTransaction in Own Shares
13th Apr 20263:29 pmRNSDirector/PDMR Shareholding
13th Apr 202611:10 amRNSTransaction in Own Shares
9th Apr 20264:43 pmRNSDirector/PDMR Shareholding
7th Apr 20269:42 amRNSTransaction in Own Shares
1st Apr 202611:11 amRNSTotal Voting Rights
30th Mar 202610:55 amRNSTransaction in Own Shares
23rd Mar 202611:00 amRNSTransaction in Own Shares
18th Mar 202610:10 amRNSAnnual Financial Report and Notice of AGM
16th Mar 20269:29 amRNSTransaction in Own Shares
16th Mar 20269:29 amRNSTransaction in Own Shares
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:56 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLaunch of Buyback Programme
26th Feb 20267:00 amRNSFinal Results, Share Buyback & Leadership Changes
4th Feb 20265:29 pmRNSStatement regarding Hikma Pharmaceuticals Plc
3rd Feb 20267:00 amRNSNotice of Results
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
15th Dec 20253:59 pmRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSHikma announces CEO change and Board appointment
11th Nov 202512:13 pmRNSHolding(s) in Company
11th Nov 202511:42 amRNSDirector/PDMR Shareholding
7th Nov 202512:56 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.